Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Malonic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 1/20 | 0.50 |
| ▸ | SRR | Q9GZT4 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | FFAR3 | O14843 | 2/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.31 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Malonic Acid SCHEMBL5874776 | 0.91 | LDHA (0.60) | LDHASRRTP53FFAR3HDAC3 | |
| Malonic Acid SCHEMBL5874780 | 0.91 | LDHA (0.60) | LDHASRRTP53FFAR3HDAC3 | |
| Malonic Acid SCHEMBL15710925 | 0.90 | LDHA (0.45) | LDHASRRTP53FFAR3HDAC3 | |
| Malonic Acid SCHEMBL9635789 | 0.88 | LDHA (0.64) | LDHASRRFFAR3HDAC3HDAC1 | |
| Malonic Acid SCHEMBL15711068 | 0.82 | LDHA (0.56) | LDHASRRFFAR3HDAC3HDAC1 | |
| Malonic Acid SCHEMBL15710339 | 0.82 | LDHA (0.56) | LDHASRRFFAR3HDAC3HDAC1 | |
| Diethylamine SCHEMBL27846018 | 0.80 | TP53 (0.47) | LDHASRRTP53FFAR3HDAC3 | |
| Diethylamine SCHEMBL27846019 | 0.80 | TP53 (0.47) | LDHASRRTP53FFAR3HDAC3 | |
| Propionic Acid SCHEMBL1014332 | 0.79 | FFAR3 (0.67) | LDHASRRTP53FFAR3HDAC3 | |
| Propionic Acid SCHEMBL28428410 | 0.79 | FFAR3 (0.67) | LDHASRRTP53FFAR3HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2740738-B1 | PLATINUM COMPOUNDS FOR TREATING CELL PROLIFERATIVE DISEASE, PREPARATION METHODS AND USES THEREOF | BEIJING FSWELCOME TECH DEVELOPMENT CO LTD (CN) | 2018-03-28 | — | — | EP | disclosed |
| US-9138421-B2 | Platinum compounds for treating cell proliferative diseases, preparation method and use thereof | BEIJING FSWELCOME TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2015-09-22 | — | — | US | disclosed |
| EP-2740738-A1 | PLATINUM COMPOUNDS FOR TREATING CELL PROLIFERATIVE DISEASE, PREPARATION METHODS AND USES THEREOF | Beijing FSwelcome Technology Development Co., Ltd. (CN) | 2014-06-11 | — | — | EP | disclosed |
| US-20140142079-A1 | PLATINUM COMPOUNDS FOR TREATING CELL PROLIFERATIVE DISEASES, PREPARATION METHOD AND USE THEREOF | BEIJING FSWELCOME TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2014-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140142079-A1 | PLATINUM COMPOUNDS FOR TREATING CELL PROLIFERATIVE DISEASES, PREPARATION METHOD AND USE THEREOF | PCNA, POLI, MKI67 | LDHA 135/4885SRR 2142/4885TP53 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.